661,675 Shares in Glaukos Corporation $GKOS Purchased by William Blair Investment Management LLC

Key Points

• William Blair Investment Management purchased 661,675 Glaukos shares worth approximately $92.5 million, giving it a 1.12% stake. Institutional investors collectively own 99.04% of the company.
• Glaukos reported quarterly revenue of $185.6 million, up 49.6% year over year, and an adjusted loss of $0.14 per share that beat estimates. The company remains unprofitable, with analysts forecasting a full-year loss.
• Analyst sentiment remains favorable, with multiple firms raising price targets and 12 of 14 analysts rating the stock a Buy. However, insiders sold 113,025 shares worth approximately $19.6 million over the last quarter.

William Blair Investment Management LLC purchased a new stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 661,675 shares of the medical instruments supplier's stock, valued at approximately $92,476,000. William Blair Investment Management LLC owned approximately 1.12% of Glaukos at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Glaukos in the 2nd quarter worth approximately $1,333,318,000. Janus Henderson Group PLC increased its holdings in shares of Glaukos by 77.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier's stock valued at $575,844,000 after purchasing an additional 2,329,608 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Glaukos by 10.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier's stock valued at $292,004,000 after purchasing an additional 336,266 shares in the last quarter. Primecap Management Co. CA lifted its stake in shares of Glaukos by 49.8% in the 4th quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier's stock valued at $381,289,000 after purchasing an additional 1,123,140 shares during the period. Finally, State Street Corp lifted its stake in shares of Glaukos by 0.9% in the 4th quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier's stock valued at $239,640,000 after purchasing an additional 18,040 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Alex R. Thurman sold 20,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $180.13, for a total value of $3,602,600.00. Following the completion of the sale, the chief financial officer owned 43,906 shares of the company's stock, valued at $7,908,787.78. This represents a 31.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leana Wen sold 525 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $167.63, for a total transaction of $88,005.75. Following the sale, the director owned 21,092 shares of the company's stock, valued at $3,535,651.96. This represents a 2.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 113,025 shares of company stock valued at $19,600,006. Company insiders own 5.90% of the company's stock.

Trending Headlines about Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report
• Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends.
• Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale.
• Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article
• Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35.
• Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Truist Financial raised their price target on shares of Glaukos from $180.00 to $215.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Wall Street Zen raised Glaukos from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Piper Sandler reissued an "overweight" rating and issued a $195.00 price target (up from $165.00) on shares of Glaukos in a report on Thursday, July 30th. Needham & Company LLC upped their price objective on shares of Glaukos from $150.00 to $201.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Finally, William Blair reaffirmed an "outperform" rating on shares of Glaukos in a report on Tuesday, May 26th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $178.08.

Glaukos Stock Up 0.4%

GKOS stock opened at $185.66 on Friday. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $191.62. The company has a market cap of $10.95 billion, a price-to-earnings ratio of -57.13 and a beta of 0.78. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average of $157.38 and a two-hundred day moving average of $131.62.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm's revenue for the quarter was up 49.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.24) earnings per share. As a group, analysts forecast that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source